TELA Bio appoints Jeffrey Blizard as President; Blizard resigns from Board

TELA Bio, Inc.

Blizard resigned from Board effective June 2, 2025; no disagreement with company.
Blizard appointed President effective same date; Antony Koblish remains CEO, drops President title.
Annual base salary $475,000; target bonus 50% of salary; cash sign-on $150,000.
Equity grant: 154,100 stock options (4-yr vest) and 104,800 RSUs (4-yr annual vest).
Blizard previously Global Head of Surgical Sales at Abiomed (J&J); joined TELA Bio board June 2024.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Antony Koblish

President

TELA · TELA Bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

Antony Koblish, the Company’s current President and Chief Executive Officer, will continue in his role as Chief Executive Officer, but as of the Effective Date will no longer hold the title of President.

Departed

Jeffrey Blizard

Director

TELA · TELA Bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025.

Appointed

Jeffrey Blizard

President

TELA · TELA Bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

the Board appointed Jeffrey Blizard as the new President of the Company, effective as of June 2, 2025

Source: SEC EDGAR

accession 0001104659-25-055248

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.